ReviewCells2020
In Vivo TSPO Signal and Neuroinflammation in Alzheimer's Disease.
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 78 citations in OpenAlex.
- Influence of Translocator Protein (Life (Basel, Switzerland) · 2026Article
- Network-based disease fingerprinting with neuroinflammation PET imaging.Journal of neuroinflammation · 2026Article
- Mapping Alzheimer's disease heterogeneity with molecular imaging biomarkers.European journal of clinical investigation · 2026Review
- TSPO contributes to neuropathology and cognitive deficits in Alzheimer's disease.Journal of neuroinflammation · 2025Article
- Network-based disease fingerprinting with neuroinflammation PET imaging.Research square · 2025Article
- Integrated bioinformatics analysis unravels mitochondrial-immune crosstalk and infiltration dynamics in sepsis progression.European journal of medical research · 2025Article
- Neurosteroids and translocator protein 18 kDa (TSPO) ligands as novel treatment options in depression.European archives of psychiatry and clinical neuroscience · 2025Review
- Current advances in the structure-activity relationship (SAR) analysis of the old/new 18-kDa translocator protein ligands.Molecular diversity · 2025Review
- Exploring inflammation-related protein expression and its relationship with TSPO PET in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model.Genes, brain, and behavior · 2025Article
- Microglial activation is raised in preclinical Alzheimer's disease and associated with covert memory impairment.Frontiers in dementia · 2025Article
- A new nano-encapsulated TSPO ligand reduces neuroinflammation and improves cognitive functions in Alzheimer's disease model.Theranostics · 2025Article
- Regional desynchronization of microglial activity is associated with cognitive decline in Alzheimer's disease.Molecular neurodegeneration · 2024Article
- Early Blood-Brain Barrier Impairment as a Pathological Hallmark in a Novel Model of Closed-Head Concussive Brain Injury (CBI) in Mice.International journal of molecular sciences · 2024Article
- Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation.European journal of medical research · 2024Review
- Neurological impact of HIV/AIDS and substance use alters brain function and structure.Frontiers in medicine · 2024Review
- Memories and mimics: unveiling the potential of FDG-PET in guiding therapeutic approaches for neurodegenerative cognitive disorders.Frontiers in neurology · 2024Review
- Non-invasiveFrontiers in cellular neuroscience · 2024Review
- Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options.European archives of psychiatry and clinical neuroscience · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last decade, positron emission tomography (PET) and single-photon emission computed tomography (SPECT) in in vivo imaging has attempted to demonstrate the presence of neuroinflammatory reactions by measuring the 18 kDa translocator protein (TSPO) expression in many diseases of the central nervous system. We focus on two pathological conditions for which neuropathological studies have shown the presence of neuroinflammation, which translates in opposite in vivo expression of TSPO. Alzheimer's disease has been the most widely assessed with more than forty preclinical and clinical studies, showing overall that TSPO is upregulated in this condition, despite differences in the topography of this increase, its time-course and the associated cell types. In the case of schizophrenia, a reduction of TSPO has instead been observed, though the evidence remains scarce and contradictory. This review focuses on the key characteristics of TSPO as a biomarker of neuroinflammation in vivo, namely, on the cellular origin of the variations in its expression, on its possible biological/pathological role and on its variations across disease phases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.